AGMB ▼ -2.8% - AgomAb Therapeutics NV
$AGMB - Agomab Announces First Patient Dosed in Global NOV-ERA Phase 2b Study of Ontunisertib in Fibrostenosing Crohn's Disease
13-OCT-2026 04:05 PM ET
Share this post
More filings for $AGMB
AGMB ▲ +4.3% - AgomAb Therapeutics NVOct 8, 2026AGMB ▲ +0.8% - AgomAb Therapeutics NVOct 1, 2026AGMB ▼ -6.0% - AgomAb Therapeutics NVSep 14, 2026AGMB ▼ -8.1% - AgomAb Therapeutics NVSep 11, 2026AGMB ▲ +8.6% - AgomAb Therapeutics NVSep 3, 2026
View full $AGMB filing history →💬 Comments
Loading comments…
Leave a comment